Evidence map›Paper›PMID 41823417›Full record

ReviewmBio2026

The contribution of viral toxins to infection and pathogenesis.

Scott B Biering, Henry Puerta-Guardo, Felix Pahmeier, Vasiliya Kril, Eva Harris

Abstract readReview
In one paragraph

Review in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Scott B BieringDepartment of Molecular Biology, School of Biological Sciences, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0003-1991-629X
Henry Puerta-GuardoLaboratorio de Virologia, CIR-Biomedicas y Unidad Colaborativa de Bioensayos Entomologicos (UCBE), Universidad Autonoma de Yucatan, Merida, Mexico.ORCID 0000-0003-3050-4480
Felix PahmeierDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, USA.ORCID 0000-0002-7445-2259
Vasiliya KrilDepartment of Molecular Biology, School of Biological Sciences, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0002-4394-4146
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, USA.ORCID 0000-0002-7238-4037

Funding

Research Project 4: Mining human antibody responses to inform vaccine and therapeutic designU19AI181977 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Kartik Chandran · 2024 to 2026
$56.1M
Host factors and viral determinants mediating flavivirus NS1 tissue-specific endothelial dysfunction and vascular leakR01AI168003 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Eva Harris · 2022 to 2026
$3.2M
Elucidating the roles of the beta-2 adrenergic receptor and epidermal growth factor receptor in flavivirus NS1-mediated endothelial dysfunctionK22AI170797 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BIERING, SCOTT BENJAMIN · 2024 to 2025
$270k
NIAID NIH HHS K22 AI170797NIAID NIH HHS R01 AI168003NIAID NIH HHS U19 AI181977
6 · The paper itself

Abstract

The process by which viruses cause disease, viral pathogenesis, is the result of both infection of cells and the host immune response. A less studied but equally important contributor to viral pathogenesis is viral dissemination, the capacity of a virus to move from the primary site of infection, traverse physiological barriers, and gain access to secondary sites of infection. This dictates viral tropism and pathogenesis, but the mechanisms governing barrier crossing are incompletely understood. While the presence of viral receptors on cells is a major determinant of viral tropism and a prerequisite for infection, it does not completely explain the capacity of viruses to enter a tissue. Our recent work has begun to characterize the contribution of soluble viral proteins, acting as "viral toxins," to viral dissemination, tissue tropism, and overall pathogenesis within an infected host. In this review, we discuss the characteristics of these viral toxins, which are soluble or surface-exposed viral proteins that can interact with endothelial and/or epithelial barriers, as well as immune cells, to trigger signaling pathways, resulting in the transient breakdown of cellular structures maintaining barrier integrity. The disruption of these barriers induces vascular leak and facilitates virus dissemination, influencing viral tropism and pathogenesis. Importantly, blocking this process prevents leak, viral dissemination, and severe disease during infection, highlighting the value of therapeutic intervention against viral toxin activity. Here, we summarize our current understanding of recently discovered viral toxins from the

Indexed as

Viral ProteinsVirus DiseasesVirusesAnimalsHost-Pathogen InteractionsHumansViral TropismViral ProteinsCCHFV GP38Crimean-Congo hemorrhagic fever virusdengue virusDENV NS1Ebola virusEBOV GPSARS-CoV-2SARS-CoV-2 Spikevascular leakviral disseminationviral pathogenesis

Identifiers

PMID41823417
PMCPMC13059731

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.